Grant: Master's Award: Canada Graduate Scholarships
University of British Columbia
$17,500.00
Role of complement opsonin C1q in the synaptic pathology of schizophrenia
FY 2023-24
Summary
Schizophrenia (SCZ) is a severe psychiatric disorder that has significant effects on those diagnosed with the illness, their families, and society. Although the underlying causes are unknown, recent evidence suggests that the immune system may be dysregulated in this disorder. The complement system is a major player in the immune system, and also contributes to normal central nervous system function. Complement C1q is the intiating protein of the complement system's classical pathway. C1q dysregulation and downstream complement activation is thought to contribute to synaptic dysfunction in SCZ. However, the specific molecular mechanisms by which C1q expression influences SCZ pathophysiology is unknown. Investigations in animals models indicate that C1q may play a role in the development of synaptic connections by tagging synapses for pruning and engulfment by microglia, however, it is yet to be determined whether high C1q levels in subjects with SCZ mediate synaptic loss. Therefore, this study aims to determine whether complement opsonin C1q mRNA and protein levels are associated with synaptic density in the human brain, and whether variations in complement levels in subjects with SCZ are associated with density of specific types of synapses. The proposed study will enhance current knowledge of the disorder, including its relationship with the complement system and potential molecular mechanisms through which brain structure and function are altered. The findings of this study, in the longterm, may elucidate novel therapies that can improve patient outcomes.
Department
Program
Master's Award: Canada Graduate Scholarships
Recipient
Location
British Columbia, Canada
Recipient Type
Academia
Type
Grant
Source
CIHR Funding Decisions Database
As published
Id
506160
Name
Kasturi Sangeetha A
Region
British Columbia
Country
Canada
Orgtype
Institution Paid; Research Institution
Prcname2
Special Cases - Awards Programs
Projecttitle
Role of complement opsonin C1q in the synaptic pathology of schizophrenia
Programtype2
Studentship Programs
Orgnameinp2
University of British Columbia
Cihramount2
$17,500
Cihrequipment2
$0
Programname2
Master's Award: Canada Graduate Scholarships
Keyworddelim
Biological Mechanisms; Complement System; Gene Expression; Glial Cells; Mood Disorder; Pathophysiology; Schizophrenia; Syanptic Pruning; Synapse; Synaptic Plasticity
Abstract
Schizophrenia (SCZ) is a severe psychiatric disorder that has significant effects on those diagnosed with the illness, their families, and society. Although the underlying causes are unknown, recent evidence suggests that the immune system may be dysregulated in this disorder. The complement system is a major player in the immune system, and also contributes to normal central nervous system function. Complement C1q is the intiating protein of the complement system's classical pathway. C1q dysregulation and downstream complement activation is thought to contribute to synaptic dysfunction in SCZ. However, the specific molecular mechanisms by which C1q expression influences SCZ pathophysiology is unknown. Investigations in animals models indicate that C1q may play a role in the development of synaptic connections by tagging synapses for pruning and engulfment by microglia, however, it is yet to be determined whether high C1q levels in subjects with SCZ mediate synaptic loss. Therefore, this study aims to determine whether complement opsonin C1q mRNA and protein levels are associated with synaptic density in the human brain, and whether variations in complement levels in subjects with SCZ are associated with density of specific types of synapses. The proposed study will enhance current knowledge of the disorder, including its relationship with the complement system and potential molecular mechanisms through which brain structure and function are altered. The findings of this study, in the longterm, may elucidate novel therapies that can improve patient outcomes.
Competitiondate
202312
Approvedterm2
1 yr 0 mth
Pinamesdelim
Kasturi, Sangeetha A
Approvedterm
1 an 0 mois
Cihrcontribution2
~ $17,500~ $0~